APLLTD

- Trading window closure for dealing in company securities begins from 1st October, 2026. - Closure remains effective until 48 hours after declaration of Unaudited Financial Results for the quarter and half-year ending 30th September, 2026.

- Investor/Analyst Meeting Schedule - Meeting Date: 23rd September, 2026 - Meeting Time: 10:00 AM onwards - Type: One-to-one meetings with institutional investors/analysts

- USFDA has issued an Establishment Inspection Report (EIR) for Alembic Pharmaceuticals' Bioequivalence Facility in Vadodara, Gujarat. - The inspection, conducted from March 3-7, 2025, has been closed.

- Alembic Pharmaceuticals Limited successfully completed an unannounced USFDA onsite Bioequivalence inspection at its Vadodara facility. - The inspection concluded with no Form 483 observations. - The inspection was conducted from August 31, 2026, to September 10, 2026.

- Alembic Pharmaceuticals Limited incorporated a Wholly Owned Subsidiary (WOS), Alembic Pharmaceuticals Global FZCO, in Dubai, UAE on August 24, 2026. - The WOS aims to explore new business opportunities and to promote, sell, and distribute pharmaceutical products. - The total subscription cost for 100% shareholding is AED 100,000.

- Investor/Analyst Meetings Schedule - Dates: September 01, 2026 and September 02, 2026 - Participants include Dolat Capital, Equirus Securities, 360 ONE Capital, ICICI Securities, Ashmore (Fund), HSBC, BOB Capital Markets Itd, Nirmal Bang, and Yes Securities. - Meetings will be In-Person (Mumbai) and Virtual. - No Unpublished Price Sensitive Information (UPSI) will be shared during the meetings.

- Investor/Analyst Meetings Schedule - Dates: September 01, 2026 and September 02, 2026 - Meetings with: Dolat Capital, Equirus Securities, 360 ONE Capital, ICICI Securities, Ashmore (Fund), HSBC, BOB Capital Markets Itd, Nirmal Bang, Yes Securities - Format: In-person (Mumbai) and Virtual - No Unpublished Price Sensitive Information will be shared.

- Mr. Chirag Shukla has been appointed as Company Secretary & Compliance Officer (Key Managerial Personnel). - The appointment is effective from August 20, 2026. - He is a qualified Company Secretary and Law Graduate with over 19 years of experience.

- Ms. Manisha Saraf resigned from the position of Company Secretary & Compliance Officer (Key Managerial Personnel) and Nodal Officer. - Her resignation is effective from 10th August, 2026, to pursue a new opportunity for career growth and development.

- FY27 overall growth outlook improved from low double-digit to mid-teen range. - US business growth outlook revised up to mid to high teens for FY27. - API segment expected to grow above 10% for the year. - India Human Health business expected to show positive trends in the next couple of quarters, aiming for high single-digit to low double-digit growth. - US Branded Specialty business expected to contribute positively to profit from FY28. - EBITDA margin trajectory broadly reflects operating leverage, with core margins improving to high-teens, partially offset by US branded investments (~150bps dilution). - Gross debt of ~INR1,600 crores expected to moderate in Q2/Q3, returning to March levels and aiming for ~1x EBITDA. - Planning to launch another 15 products for the rest of FY27.

- Proceedings of the 16th Annual General Meeting held on August 5, 2026. - Adopted FY26 financial statements and declared dividend for FY26. - Re-appointed Mr. Pranav Amin and appointed Mr. Sujit Bhayani as Independent Director. - Voting results to be declared by August 7, 2026.

- Alembic Pharmaceuticals Limited has submitted the audio recording of its Post Results Conference Call held on August 4, 2026. - The recording is available on the company's website at alembicpharmaceuticals.com/quarterly-results.

- Consolidated Revenue ₹2,150 Cr vs ₹1,711 Cr (▲26% YoY) - EBITDA ₹523 Cr vs ₹432 Cr (▲21% YoY) - PAT ₹173 Cr vs ₹154.5 Cr (▲12% YoY) - EBITDA Margin 24% vs 25.3% (▼130bps)

- Consolidated Revenue ₹2150 Cr vs ₹1711 Cr (▲26% YoY) - EBITDA ₹523 Cr vs ₹432 Cr (▲21% YoY) - PAT ₹173 Cr vs ₹154 Cr (▲12% YoY) - EBITDA Margin 24% vs 25.3% (▼130bps)

- Consolidated Revenue ₹2,149.77 Cr vs ₹1,710.72 Cr (▲25.66% YoY) - EBITDA ₹332.25 Cr vs ₹280.89 Cr (▲18.28% YoY) - PAT ₹175.33 Cr vs ₹155.09 Cr (▲13.05% YoY) - EBITDA Margin 16.18% vs 16.84% (▼66bps)

- Consolidated Revenue ₹2,149.77 Cr vs ₹1,710.72 Cr (▲25.66% YoY) - EBITDA ₹347.88 Cr vs ₹287.97 Cr (▲20.80% YoY) - PAT ₹172.36 Cr vs ₹153.64 Cr (▲12.19% YoY) - EBITDA Margin 16.18% vs 16.84% (▼66 bps)